|Mr. Staffan Stromberg Ph.D.||Chief Exec. Officer||N/A||N/A||1967|
|Mr. Robert Molander||Chief Commercial Officer||N/A||N/A||1965|
|Ms. Maria Ekdahl||Chief Financial Officer||N/A||N/A||1973|
|Mr. Anders Kronström||Chief Operating Officer||N/A||N/A||1967|
|Prof. Jonas Rastad M.D., Ph.D.||Chief Medical Officer & Chief Scientific Officer||N/A||N/A||1950|
Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, to prevent necrotizing enterocolitis, as well as to improve feeding tolerance affecting premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe disease in infants. The company was founded in 2013 and is based in Stockholm, Sweden.
Infant Bacterial Therapeutics AB (publ)’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.